CKF Tide Tables

KLOW-80 (“Deadpool Stack”)

Quick Facts

Property Value
Category Regenerative Multi-Peptide Blend
Risk Level Moderate/High
Administration Subcutaneous Injection
Typical Frequency Nightly
Estimated Half-Life Blend-Dependent / Multi-Phase Activity
Primary Research Interest Injury Recovery / Tissue Repair / Inflammation Reduction
Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and regenerative compounds. KLOW 80 (“Deadpool Stack”) is a multi-compound experimental peptide blend with limited formal human safety data. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

1. Reconstitution Guide

  • Blend Composition: GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg / KPV 10 mg
  • Blend Ratio: 5 : 1 : 1 : 1
  • Total Vial Size: 80 mg
  • Dilutant Type: BAC Water
  • Amount of Dilutant Added: 2 mL
  • Final Concentration: 40 mg/mL total blend concentration

At this concentration:
• 10 units = 0.10 mL
• 20 units = 0.20 mL

2. Route of Administration

KLOW 80 is most commonly discussed as a subcutaneous injectable regenerative peptide blend.

  • Primary Route: SubQ Injection
  • Preferred Timing: Evening / nighttime administration
  • Administration Notes: Some users prefer administration near injured tissues, though systemic effects are also commonly discussed

3. Typical Research Protocols

  • Product Strength: 40 mg/mL total blend concentration
  • Typical Delivered Amount: 10–20 units daily
  • Frequency: Each PM
  • Cycle Length: 8–12 weeks on, PRN (as needed) for injury recovery
  • Special Notes: Injection site sting is very common due to the high concentration of copper peptide. The solution should appear blue or turquoise when properly mixed. Swirl gently only and avoid vigorous mixing. Avoid prolonged room temperature exposure.

4. Summary

KLOW 80 (“Deadpool Stack”) is a regenerative multi-peptide blend combining GHK-Cu, BPC-157, TB-500, and KPV into a single formulation intended to support tissue recovery, inflammation modulation, collagen signaling, and soft tissue repair.

The blend attempts to combine multiple complementary regenerative pathways into a single injectable preparation.

5. Mechanism of Action

KLOW 80 combines several experimental peptides with overlapping but distinct regenerative signaling properties:

  • GHK-Cu: Collagen signaling, copper peptide activity, tissue remodeling
  • BPC-157: Angiogenesis and soft tissue recovery signaling
  • TB-500: Cellular migration and tissue repair support
  • KPV: Anti-inflammatory and immune modulation signaling

Together, the blend is intended to support:

  • Tissue remodeling
  • Inflammation reduction
  • Recovery support
  • Collagen signaling
  • Soft tissue repair pathways

6. Potential Benefits

  • Potential acceleration of soft tissue recovery
  • Reduced inflammation signaling
  • Enhanced collagen support
  • Improved recovery from injury or training stress
  • Potential skin and connective tissue benefits
  • Broad regenerative pathway support

7. Potential Risks / Side Effects

Moderate/High

  • Injection site irritation or stinging
  • Localized redness or swelling
  • Fatigue
  • Nausea
  • Potential abnormal angiogenesis concerns
  • Limited long-term human safety data
  • Possible immune or inflammatory signaling alterations

8. Half-Life

Because KLOW 80 is a multi-peptide blend, pharmacokinetics vary significantly between individual components.

Some components demonstrate short plasma half-lives while downstream regenerative signaling effects may persist substantially longer.

9. Storage Information

  • Store refrigerated before and after reconstitution
  • Protect from direct light exposure
  • Avoid repeated freeze-thaw cycles
  • Avoid prolonged room temperature exposure
  • Maintain sterile handling practices during preparation

10. Contraindications / Warnings

  • Active cancer or cancer history
  • Pregnancy or breastfeeding
  • Use alongside experimental angiogenic compounds
  • Known hypersensitivity to peptide compounds
  • Severe inflammatory or autoimmune conditions

11. Research References

  • PubMed
  • NIH Publications
  • Experimental regenerative medicine literature
  • Peer-reviewed tissue repair journals